Novel group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors
The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | Chinese English |
Published |
28.09.2016
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds.
类新的STAT3通路抑制剂和癌干细胞通路抑制剂。本发明涉及类新的癌干细胞通路(CSCP)抑制剂的用途;利用此类化合物治疗顽固性、复发性或转移性癌症的方法;通过利用此类化合物以特定施用策略选择性杀死癌细胞的方法;通过抑制Stat3通路靶向癌干细胞的方法;利用新化合物治疗哺乳动物异常Stat3通路活性相关病情或紊乱的方法;以及制备此类化合物及其中间体的方法;相关化合物的药物组合物;和施用这些化合物的具体方法。 |
---|---|
Bibliography: | Application Number: CN201610134121 |